Trial Information

Official Title: Efficacy and Safety Study of MCI-186 for Treatment of the Patients With Amyotrophic Lateral Sclerosis (ALS) 2

Summary

The primary objective of the study is to confirm the efficacy of 60 mg of MCI-186 via intravenous drip infusion once a day in the patients with ALS based on the changes in the revised ALS functional rating scale (ALSFRS-R) scores after 24 weeks administration in double-blind, placebo-controlled manner. The study is also to examine the safety of MCI-186 to the ALS patients.

Phase: Phase 3

Sponsor: Mitsubishi Tanabe Pharma Corporation

Overall Contacts:

Clinical Trials Information Desk

cti-inq-ml@ml.mt-pharma.co.jp